Description: A groundbreaking approach to combat solid tumor cancers.

Problem: Addressing challenges in treating metastatic breast cancer.

Solution: Utilizing cell therapeutics showing promise in resistant cases.

Data: 60% of patients extended life in trials, with animal models reversing metastasis.

Impact: A potential game-changer in the quest for effective cancer treatment.

Technology: Mature cells reprogrammed into pluripotent stem cells.

Vision: Bringing hope to countless patients by curing solid tumors.

Scalability: The technology holds potential for global implementation.

Stage: Seeking Series B financing with a target of $25 million.

Capital: $45 million invested over 20 years.

Use of Funds: Investment drives production, commercialization, and market introduction.

Risk Factors: Acknowledges inherent risks in biotechnology.